Compare Gilead Sciences, Inc. (GILD) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marriott International Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while Marriott International Inc trades at $360.95 (market cap $94.16B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Marriott International Inc for 164 Days on average.
| GILD | MAR | |
|---|---|---|
Market Cap | $182.40B | $94.16B |
Volume | 4,469,821 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $402.54 |
52-Week Low | $116.74 | $259.04 |
Typical Hold Time | 111 Days | 164 Days |
Enterprise Value | $205.46B | $111.47B |
Dividend Yield | 2.23% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Marriott International (MAR) trades at $356.50, down 1.32% on the day, with a bullish technical signal from moving averages and support near $354. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%, though the P/E of 36.9 suggests a premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share payable in September 2026. Analyst consensus is a Buy with a $386.71 price target, indicating potential upside.
The outlook for MAR is positive, supported by strong travel demand and strategic partnerships, but risks include high debt levels and sensitivity to economic cycles. With institutional interest mixed and a neutral sentiment from oscillators, the stock offers growth potential tempered by valuation concerns and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
